|
US5824311A
(en)
|
1987-11-30 |
1998-10-20 |
Trustees Of The University Of Pennsylvania |
Treatment of tumors with monoclonal antibodies against oncogene antigens
|
|
US4870287A
(en)
|
1988-03-03 |
1989-09-26 |
Loma Linda University Medical Center |
Multi-station proton beam therapy system
|
|
US5348878A
(en)
|
1990-05-10 |
1994-09-20 |
Dana-Farber Cancer Institute |
Class I MHC-restricted T-T hybridomas, and a CD8-transfected BW5147, fusion partner therefor
|
|
US5801029A
(en)
|
1993-02-16 |
1998-09-01 |
Onyx Pharmaceuticals, Inc. |
Cytopathic viruses for therapy and prophylaxis of neoplasia
|
|
US5801005A
(en)
|
1993-03-17 |
1998-09-01 |
University Of Washington |
Immune reactivity to HER-2/neu protein for diagnosis of malignancies in which the HER-2/neu oncogene is associated
|
|
GB9506466D0
(en)
|
1994-08-26 |
1995-05-17 |
Prolifix Ltd |
Cell cycle regulated repressor and dna element
|
|
US5760395A
(en)
|
1996-04-18 |
1998-06-02 |
Universities Research Assoc., Inc. |
Method and apparatus for laser-controlled proton beam radiology
|
|
US5739169A
(en)
|
1996-05-31 |
1998-04-14 |
Procept, Incorporated |
Aromatic compounds for inhibiting immune response
|
|
CZ298364B6
(cs)
|
1998-02-05 |
2007-09-05 |
Smithkline Beecham Biologicals S. A. |
Deriváty antigenu asociovaných s nádory z MAGE rodiny a sekvence nukleových kyselin kodující tyto deriváty, jejich použití pro prípravu fúzních proteinu a prostredku pro vakcinaci
|
|
KR20010034512A
(ko)
|
1998-02-19 |
2001-04-25 |
베렌슨, 론 |
림프구 활성화 조절을 위한 조성물 및 그 방법
|
|
US6410319B1
(en)
|
1998-10-20 |
2002-06-25 |
City Of Hope |
CD20-specific redirected T cells and their use in cellular immunotherapy of CD20+ malignancies
|
|
PT1187629E
(pt)
|
1999-04-19 |
2005-02-28 |
Glaxosmithkline Biolog Sa |
Composicao adjuvante que compreende saponina e um oligonucleotido imunoestimulador
|
|
US7754208B2
(en)
|
2001-01-17 |
2010-07-13 |
Trubion Pharmaceuticals, Inc. |
Binding domain-immunoglobulin fusion proteins
|
|
US7514537B2
(en)
*
|
2001-04-30 |
2009-04-07 |
City Of Hope |
Chimeric immunoreceptor useful in treating human gliomas
|
|
FR2827302B1
(fr)
|
2001-07-13 |
2003-10-10 |
Genoway |
Cellule et animal transgenique modelisant la presentation antigenique humaine et leurs utilisations
|
|
US20060104968A1
(en)
|
2003-03-05 |
2006-05-18 |
Halozyme, Inc. |
Soluble glycosaminoglycanases and methods of preparing and using soluble glycosaminogly ycanases
|
|
US7871607B2
(en)
|
2003-03-05 |
2011-01-18 |
Halozyme, Inc. |
Soluble glycosaminoglycanases and methods of preparing and using soluble glycosaminoglycanases
|
|
US20050042217A1
(en)
|
2003-03-19 |
2005-02-24 |
Yan Qi |
Specific inhibition of allorejection
|
|
CA2534639C
(en)
|
2003-07-31 |
2013-07-30 |
Immunomedics, Inc. |
Anti-cd19 antibodies
|
|
US7714119B2
(en)
|
2004-07-13 |
2010-05-11 |
Biosante Pharmaceuticals, Inc. |
AAV vector compositions and methods for enhanced expression of immunoglobulins using the same
|
|
CA2574802A1
(en)
|
2004-07-20 |
2006-02-02 |
Isogenis, Inc. |
Specific inhibition of autoimmunity and diseases associated with autoantigens
|
|
WO2006023598A2
(en)
*
|
2004-08-19 |
2006-03-02 |
University Of Maryland, Baltimore |
Prostate-specific antigen-derived mhc class ii-restricted peptides and their use in vaccines to treat or prevent prostate cancer
|
|
US20120064100A1
(en)
|
2009-03-18 |
2012-03-15 |
Simon Barry |
Biomarkers and uses thereof
|
|
EP2601521B1
(en)
|
2010-08-06 |
2018-05-02 |
Ludwig-Maximilians-Universität München |
Identification of t cell target antigens
|
|
MX370148B
(es)
|
2012-10-02 |
2019-12-03 |
Memorial Sloan Kettering Cancer Center |
Composiciones y su uso para inmunoterapia.
|
|
EP2931893A1
(en)
|
2012-12-13 |
2015-10-21 |
Universität Leipzig |
T-cell modulation by exon skipping
|
|
RS60026B1
(sr)
*
|
2013-02-18 |
2020-04-30 |
Vegenics Pty Ltd |
Molekuli koji vezuju ligande i njihove upotrebe
|
|
CN111484999B
(zh)
*
|
2013-02-20 |
2024-10-25 |
瑞泽恩制药公司 |
人源化的t细胞共受体的小鼠
|
|
US10975137B2
(en)
|
2014-11-06 |
2021-04-13 |
University Of Maryland, Baltimore |
CD8a and t cell receptor variants and methods of using same in modulating immune cell responses
|
|
MY191537A
(en)
*
|
2014-12-05 |
2022-06-30 |
Memorial Sloan Kettering Cancer Center |
Chimeric antigen receptors targeting b-cell maturation antigen and uses thereof
|
|
CN108064176A
(zh)
|
2015-04-22 |
2018-05-22 |
库瑞瓦格股份公司 |
用于治疗肿瘤疾病的含有rna的组合物
|
|
SG11201803419PA
(en)
*
|
2015-10-30 |
2018-05-30 |
The Regents Of The Universtiy Of California |
Methods of generating t-cells from stem cells and immunotherapeutic methods using the t-cells
|
|
JP7123794B2
(ja)
|
2015-12-09 |
2022-08-23 |
メモリアル スローン ケタリング キャンサー センター |
免疫細胞組成物及びそれを使用する方法
|
|
US11661455B2
(en)
|
2016-02-05 |
2023-05-30 |
Orionis Biosciences BV |
Chimeric protein comprising an interferon alpha 2mutant and a PD-L1 binding moiety
|
|
CN116769054A
(zh)
*
|
2016-02-05 |
2023-09-19 |
奥里尼斯生物科学私人有限公司 |
双特异性信号传导剂及其用途
|
|
US11446398B2
(en)
|
2016-04-11 |
2022-09-20 |
Obsidian Therapeutics, Inc. |
Regulated biocircuit systems
|
|
CN109996868A
(zh)
|
2016-09-23 |
2019-07-09 |
弗雷德哈钦森癌症研究中心 |
特异性用于次要组织相容性(h)抗原ha-1的tcr及其用途
|
|
KR102879522B1
(ko)
*
|
2017-03-03 |
2025-11-04 |
엑수마 바이오테크, 코포레이션 |
림프구를 형질도입 및 팽창시키고 이들의 활성을 조절하기 위한 방법 및 조성물
|
|
JP7037577B2
(ja)
|
2017-03-15 |
2022-03-16 |
フレッド ハッチンソン キャンサー リサーチ センター |
高親和性ｍａｇｅ－ａ１特異的ｔｃｒ及びその使用
|
|
WO2019028295A1
(en)
*
|
2017-08-02 |
2019-02-07 |
La Jolla Institute For Allergy And Immunology |
COMPOSITIONS AND METHODS FOR ISOLATING AND / OR GENERATING SUB-ASSEMBLIES OF SPECIFIC CD4 + AND CD8 + T LYMPHOCYTES
|
|
CA3097396A1
(en)
|
2018-04-19 |
2019-10-24 |
Baylor College Of Medicine |
Reprogramming cd4 t cells into cytotoxic cd8 cells by forced expression of cd8ab and class 1 restricted t cell receptors
|
|
WO2020049496A1
(en)
|
2018-09-05 |
2020-03-12 |
Glaxosmithkline Intellectual Property Development Limited |
T cell modification
|
|
GB201819540D0
(en)
|
2018-11-30 |
2019-01-16 |
Adaptimmune Ltd |
T cell modification
|